Search research articles
Contact Us
Filters
Showing results (111-120 of 2,246) with videos related to
Page
of 225
Sort By:
ESMO Open
|
November 16, 2016
Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours?
A Addeo, V Fusco, J P Braybrooke
ESMO Open
|
November 16, 2016
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Teresa Troiani, Stefania Napolitano, Carminia Maria Della Corte, et al.
ESMO Open
|
August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer
J Tabernero, A Grothey, D Arnold, et al.
ESMO Open
|
September 9, 2022
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
R Wuerstlein, P Ellis, F Montemurro, et al.
ESMO Open
|
November 6, 2025
Letter to the Editor Re: Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06: Clinical validation of the VENTANA PATHWAY anti-HER2/neu (4B5) assay in HER2-low and HER2-ultralow breast cancer
Y Horimoto
ESMO Open
|
April 1, 2025
Response to: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis
L Rimassa, C Astolfi, F Piscaglia
ESMO Open
|
October 18, 2023
In the literature: September 2023
A Lamarca, V Moreno, V Gambardella, et al.
ESMO Open
|
October 11, 2023
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
J R Gosney, S Peters
ESMO Open
|
September 28, 2023
From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
J E Rodriguez, S Ponce-Aix
ESMO Open
|
February 28, 2021
Small-cell lung cancer in never-smokers
M Torres-Durán, M T Curiel-García, A Ruano-Ravina, et al.
Page
of 225
Search research articles
Search
Showing results (111-120 of 2,246) with videos related to
Sort By:
Page
of 225
ESMO Open
|
November 16, 2016
Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours?
A Addeo, V Fusco, J P Braybrooke
ESMO Open
|
November 16, 2016
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Teresa Troiani, Stefania Napolitano, Carminia Maria Della Corte, et al.
ESMO Open
|
August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer
J Tabernero, A Grothey, D Arnold, et al.
ESMO Open
|
September 9, 2022
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
R Wuerstlein, P Ellis, F Montemurro, et al.
ESMO Open
|
November 6, 2025
Letter to the Editor Re: Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06: Clinical validation of the VENTANA PATHWAY anti-HER2/neu (4B5) assay in HER2-low and HER2-ultralow breast cancer
Y Horimoto
ESMO Open
|
April 1, 2025
Response to: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis
L Rimassa, C Astolfi, F Piscaglia
ESMO Open
|
October 18, 2023
In the literature: September 2023
A Lamarca, V Moreno, V Gambardella, et al.
ESMO Open
|
October 11, 2023
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
J R Gosney, S Peters
ESMO Open
|
September 28, 2023
From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
J E Rodriguez, S Ponce-Aix
ESMO Open
|
February 28, 2021
Small-cell lung cancer in never-smokers
M Torres-Durán, M T Curiel-García, A Ruano-Ravina, et al.
Page
of 225